On the stiffness scale, Merck saw a 3.0 reduction in the pimicotinib group and 0.57 dip in the placebo cohort. The figures ...
German sci-tech giant Merck is very optimistic about its prospects in the Chinese market and will continue to strengthen its ...
Merck (MRK) will be in focus as company beats revenue forecasts despite in line earnings amid strong Keytruda sales in Q3 ...
While Merck's oncology powerhouse Keytruda delivered another multibillion-dollar sales haul in the third quarter, regional ...
Therivaâ„¢ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced ...
Theriva Biologics (TOVX) announced selection as one of five finalists for Merck KGaA’s EMEA Advance Biotech Grant. Finalists for the ...
We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...
Winner to be Presented at BIO-Europe 2024 in Stockholm, SwedenROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing ...
Likewise, the rate of overall survival was not reached in the pembrolizumab group and was 31 months without pembrolizumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback